Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

437 Reports from FirstWord

   
  • The ROI of Orphan Drugs-- Ensuring optimal returns (2017)

    ... lives; there's also the lure of potentially lucrative commercial benefits for those that succeed. But finding the right balance between return on investment (ROI) and optimum patient access is proving difficult. And with only 415 ... Read More

  • The Importance of Real World Evidence in Orphan Drugs

    ... rare conditions. Progress has been made with real world data (RWD) and real world evidence (RWE), however there are still gaps that must be addressed. The Importance of Real World Evidence in Orphan Drugs explores ... Read More

  • Market Access Impact (EU5) [T2DM] (Orals)

    ... for Type 2 Diabetes Mellitus in the EU5 countries, and more brands lose market share because of them. Certain barriers are contributing more than most to these declines, but it might not be what you’d ... Read More

  • Market Access Impact (US) [T2DM] (Orals)

    ... Type 2 Diabetes Mellitus in the US. According to the diabetologists and primary care physicians we surveyed, that’s a problem with no single solution. Many of them experience as many as 2 different barriers with ... Read More

  • Market Access Impact (US) [T2DM] (Injectables)

    ... Type 2 Diabetes Mellitus in the US. According to the diabetologists and primary care physicians we surveyed, that’s a problem with no single solution. Many of them experience as many as 2 different barriers with ... Read More

  • Market Access Impact (EU5) [T2DM] (Injectables)

    ... for Type 2 Diabetes Mellitus in the EU5 countries, and more brands lose market share because of them. Certain barriers are contributing more than most to these declines, but it might not be what you’d ... Read More

  • Value Added Services in Oncology -- Payer views

    ... interest in beyond-the-pill services that improve patient adherence, positively impact health outcomes and reduce the overall cost burden. Yet pharma does not consult with payers on VAS development and fails to fully utilise the real ... Read More

  • Artificial Intelligence in the Pharmaceutical Industry

    ... and improved clinician/patient education and support. But pharma remains dangerously behind the AI curve and advocates say the time is now for pharma to get on board with the investment and organisational changes that will ... Read More

  • Medical Affairs Reputations (US) [Haemophilia A]

    ... A medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want ... Read More

  • Medical Affairs Reputations (EU5) [Haemophilia A]

    ... Germany, Italy and Spain) the performance of haemophilia A medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what ... Read More

  • Medical Affairs Reputations (EU5) [Haemophilia B]

    ... Germany, Italy and Spain) the performance of haemophilia B medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what ... Read More

  • Medical Affairs Reputations (US) [Myeloma]

    ... of multiple myeloma medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what ... Read More

  • Medical Affairs Reputations (EU5) [Myeloma]

    ... (UK, France, Germany, Italy and Spain) the performance of multiple myeloma medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find ... Read More

  • Market Access Impact (US) [RA]

    ... US. High costs and limited formulary access are preventing rheumatologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers ... Read More

  • Melanoma [2017]

    ... emerging from the late-stage pipeline, but in a competitive landscape which assets will stand out? Want to find out more? Learn how KOLs see the malignant melanoma market evolving in Melanoma: KOL Insight (2017). Twelve ... Read More

  • Multiple Sclerosis [2017]

    ... leaders (KOLs) are excited about Ocrevus’ approval in relapsing and progressive forms of the disease and Mavenclad’s European approval gives patients another treatment choice, but which therapy will stand out in an evolving and competitive ... Read More

  • Orphan Drug Launches: Case Studies

    ... therapies. Lack of awareness, greater scrutiny of value, and the difficulty of gathering clinical evidence from a relatively small patient population are just some of the pertinent issues. By comparing the experiences of 8 market ... Read More

  • Market Access Impact (EU5) [RA]

    ... The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, where ... Read More

  • Market Access Team Structure and Function -- Industry Survey 2017

    ... on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017 draws on detailed survey responses from 100 market access executives within the top 100 pharmaceutical companies. Presented as easy to assess charts, ... Read More

  • Medical Affairs Reputations (US) [Haemophilia B]

    ... B medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want ... Read More

  • NPS+ (US) [MS]

    ... greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ Multiple Sclerosis (US) ... Read More

  • NPS+ (EU5) [MS]

    ... greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ Multiple Sclerosis (EU5) ... Read More

  • Commercialisaton of Biosimilars: Multifunctional teamwork for success

    ... in this high stakes market? Against a backdrop of ever increasing competition and great expectations, the most effective and lucrative commercial strategies for biosimilars are emerging. Is it a case of 'business as usual' or ... Read More

  • Commercialisation of Biologics: Benchmarking leading players

    ... are obviously attractive, but just how effective have biologics manufacturers been so far in commercialising these innovative drugs? How have key players navigated stumbling blocks such as inconsistent patient and physician acceptance and growing payer ... Read More

  • Customer Engagement: Benchmarking Pharma Companies

    ... away from the brand focus of old and develop new customer-focused engagement strategies. What have the front-runners achieved so far and how have they tackled this new challenge? Customer Engagement: Benchmarking Leading Pharma Companies provides ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook